EUVIMEDEUVIMED entdecken
Crossref

RNF152 inhibits immune evasion in clear cell renal cell carcinoma by promoting the ubiquitination of PD-L1

Qiang Wang, Yue-Ru Liu, Xiu-Bo Zhu, Ji-Chao Peng, Shuang Chen

Medical Oncology · 2026

DOI: 10.1007/s12032-026-03478-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, 2026. Verfasst von Qiang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Luzhou Hospital of Traditional Chinese Medicine, No. 80 Xinglin Road, Naxi District, Luzhou, 646300, Sichuan, China. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, B7-H1 Antigen, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation of ubiquitination drives tumor progression in various cancers, including clear cell renal cell carcinoma (ccRCC). RING finger protein 152 (RNF152) is a ubiquitin E3 ligase that regulates cancer development. This study aimed to investigate the role of RNF152 in ccRCC and to elucidate the underlying molecular mechanism. RNF152 expression and its correlation with survival were analyzed through bioinformatics analysis of the RNA expression profile from TCGA. Tumor cell viability and colony formation, as well as cytotoxicity of co-cultured CD8^+ T cells, were assessed. Tumor growth and immune evasion were evaluated using a tumor-bearing mouse model. Furthermore, whether RNF152 regulates PD-L1 via ubiquitination was investigated. RNF152 was expressed at low levels in ccRCC, and high RNF152 expression correlated with better patient survival. Overexpression of RNF152 inhibited proliferation and immune evasion of ccRCC cells in vitro, while knockdown of RNF152 had the opposite effects. Moreover, RNF152 promoted degradation of PD-L1 by facilitating K48-linked polyubiquitination, and the ubiquitination site was identified as K64. Additionally, overexpression of PD-L1 counteracted the inhibition of proliferation and immune evasion induced by RNF152. In vivo, anti-PD-L1 therapy inhibited tumor growth and immune evasion in mice with RNF152 knockdown. facilitating ubiquitination of PD-L1. These findings reveal a novel regulatory mechanism in ccRCC and highlight the therapeutic potential of upregulating RNF152 to enhance anti-tumor immunity, potentially in combination with anti-PD-L1 immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesB7-H1 AntigenCarcinoma, Renal CellKidney NeoplasmsHumansUbiquitinationAnimalsMiceCell Line, TumorTumor EscapeCell ProliferationImmune EvasionGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Clear cell renal cell carcinomaImmune evasionPD-L1RNF152Ubiquitination

Substanzen

Ubiquitin-Protein LigasesB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Urology, Luzhou Hospital of Traditional Chinese Medicine, No. 80 Xinglin Road, Naxi District, Luzhou, 646300, Sichuan, China.
  • Department of Neurosurgery and Cardiothoracic Surgery, Luzhou Hospital of Traditional Chinese Medicine, Luzhou, China.
  • Department of Urology, Luzhou Hospital of Traditional Chinese Medicine, No. 80 Xinglin Road, Naxi District, Luzhou, 646300, Sichuan, China. 13550872091@163.com.

Zitieren

APA

Wang, Q., Liu, Y. R., Zhu, X. B., Peng, J. C., & Chen, S. (2026). RNF152 inhibits immune evasion in clear cell renal cell carcinoma by promoting the ubiquitination of PD-L1. Medical Oncology. https://doi.org/10.1007/s12032-026-03478-1

Vancouver

Wang Q, Liu YR, Zhu XB, Peng JC, Chen S. RNF152 inhibits immune evasion in clear cell renal cell carcinoma by promoting the ubiquitination of PD-L1. Medical Oncology. 2026. doi:10.1007/s12032-026-03478-1

BibTeX
@article{Wang2026,
  author = {Wang, Qiang and Liu, Yue-Ru and Zhu, Xiu-Bo and Peng, Ji-Chao and Chen, Shuang},
  title = {RNF152 inhibits immune evasion in clear cell renal cell carcinoma by promoting the ubiquitination of PD-L1},
  journal = {Medical Oncology},
  year = {2026},
  doi = {10.1007/s12032-026-03478-1}
}
Kostenlos starten →